Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

This Korean real-world study tracks patients with type 2 diabetes who are adding a third oral diabetes drug to their existing combination therapy (metformin plus a DPP-4 inhibitor or SGLT-2 inhibitor), to see how well this triple therapy works and whether it is safe in everyday clinical practice. **You may be eligible if...** - You are 19 or older with type 2 diabetes - You have been on a stable combination of metformin plus a DPP-4 inhibitor or SGLT-2 inhibitor for at least 8 weeks before enrollment - Your HbA1c is between 7.0% and below 10.0% - You give written consent to participate **You may NOT be eligible if...** - You have type 1 diabetes or secondary diabetes - You are already on 3 or more oral diabetes drugs - You need insulin or GLP-1 injections - You are on dialysis or have end-stage kidney disease - You have had diabetic ketoacidosis Talk to your doctor to see if this trial is right for you.